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Thymic self-antigens for the design of a negative/tolerogenic
self-vaccination against type 1 diabetes
Vincent Geenen1, Marie Mottet1, Olivier Dardenne1, Hamid Kermani1,
Henri Martens1, Jean-Marie Francois2, Moreno Galleni2, Didier Hober3,
Souad Rahmouni4 and Michel Moutschen4Before being able to react against infectious nonself-antigens,
the immune system has to be educated in the recognition and
tolerance of neuroendocrine proteins and this critical process
takes place only in the thymus. The development of the
autoimmune diabetogenic response results from a thymus
dysfunction in programing central self-tolerance to pancreatic
insulin-secreting islet b cells, leading to the breakdown of
immune homeostasis with an enrichment of islet b-cell
reactive effector T cells and a deficiency of b-cell specific
natural regulatory T cells (nTregs) in the peripheral T-
lymphocyte repertoire. Insulin-like growth factor 2 (IGF-2) is
the dominant member of the insulin family expressed during
fetal life by the thymic epithelium under the control of the
autoimmune regulator (AIRE) gene/protein. The very low
degree of insulin gene transcription in normal murine and
human thymus explains why the insulin protein is poorly
tolerogenic as demonstrated in many studies, including the
failure of all clinical trials that have attempted immune
tolerance to islet b cells via various methods of insulin
administration. On the basis of the close homology and
crosstolerance between insulin, the primary T1D autoantigen,
and IGF-2, the dominant self-antigen of the insulin family, a
novel type of vaccination, so-called ‘negative/tolerogenic self-
vaccination’, is currently being developed for the prevention
and cure of T1D. If this approach were found to be effective for
reprograming immunological tolerance in T1D, it could pave
the way for the design of other self-vaccines against
autoimmune endocrine diseases, as well as other organ-
specific autoimmune diseases.
Addresses
1University of Liege Center of Immunology (CIL), Laboratory of
Immunoendocrinology, Institute of Pathology CHU-B23, B-4000 Liege-
Sart Tilman, Belgium
2University of Liege Center of Protein Engineering (CIP), Institute of
Chemistry B6c, B-4000 Liege-Sart Tilman, Belgium
3University Lille 2, Faculty of Medicine, CHRU Lille, Laboratory of
Virology/UPRES EA 3610 Viral Pathogenesis of Type 1 Diabetes, Institut
Hippocrate, 59037 Lille, France
4 Immunology and Infectious Diseases Unit, GIGA-Research, University
of Liege, Liege-Sart Tilman, Belgium
Corresponding author: Geenen, Vincent (vgeenen@ulg.ac.be)www.sciencedirect.comCurrent Opinion in Pharmacology 2010, 10:461–472
This review comes from a themed issue on
Immunomodulation
Edited by Vincent Geenen
Available online 29th April 2010
1471-4892/$ – see front matter
# 2010 Elsevier Ltd. All rights reserved.
DOI 10.1016/j.coph.2010.04.005
‘‘Autoimmune disease can be a depressing subject. In Shake-
spearian terms, ‘it is a tale told by an idiot. . .signifying
nothing’. In more modern metaphor, it is an error made at
random in an enormous, delicately programmed computer.
Nature has no other way of handling genetic error than by
eliminating the faulty, and the physician handling autoimmune
diseases can expect no help from her.’’
Sir F. MacFarlane Burnet, 1972
Introduction
In 1965, our late Belgian colleague Willy Gepts
observed inflammatory infiltrates of mononuclear
cells invading Langerhans’ islets in the pancreas
of deceased young diabetic patients [1]. In a prophe-
tical analysis, he discussed his innovative results
with the following words: ‘It seems probable that, in
the pancreas of acute diabetics, we had the opportunity to
catch the final stages of a process which has been going on
for an indefinite time, perhaps from birth on’. Since this
pioneering work, research conducted worldwide has
firmly established that type 1 diabetes (T1D) — pre-
viously called juvenile diabetes, and insulin-dependent
diabetes — is the final result of a highly selective
autoimmune response that generates an inflammation
(insulitis), followed by the death of insulin-secreting
islet b cells in the pancreas. Incidence of T1D peaks
around 10–14 years and this disease affects 20 million
people worldwide (approximately 10% of all patients
with diabetes mellitus). The mean prevalence of
T1D in Europe is about 8 new cases per year and
per 100 000 individuals, but this prevalence is five to
six times higher in Scandinavian countries, particularly
in Finland.Current Opinion in Pharmacology 2010, 10:461–472
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The discovery of autoantibodies directed against Lan-
gerhans’ islet cells was a crucial step for further demon-
strating the autoimmune nature of the pathogenic process
in T1D [2]. Since then, the nature of autoantigens tar-
geted by these autoantibodies has been well defined, and
the three major T1D-related autoantigens are (pro)insu-
lin, the 65-kDa isoform of glutamic acid decarboxylase
(GAD65), and the tyrosine phosphatase IA-2. The islet-
specific cation efflux transporter ZnT8 (Slc30A8) and
chromogranin A were also recently reported as important
autoantigens in T1D [3,4]. However, from these auto-
antigens, only antigenic epitopes derived from (pro)insu-
lin are specific of pancreatic islet b cells. Furthermore,
there is now ample evidence that autoimmunity to
(pro)insulin is central to autoimmune diabetes pathogen-
esis both in nonobese diabetic (NOD) mice and in
humans [5,6]. Anti-insulin, anti-GAD65, and anti-IA-2
autoantibodies are very reliable markers of the auto-
immune response targeting b cells. Serum from more
than 90% of children with recent-onset T1D contains
antibodies against one or several of these autoantigens.
Their high predictive value is also established since they
can be detected several years before the clinical signs of
insulin deficiency. The predictive value of autoantibodies
against several autoantigens is higher than high titers of
one single autoantibody. If the three autoantibodies are
detected in one individual, the risk of developing T1D is
at least 80 times higher than in the general population.
The combination of autoantibodies with susceptible
genetic alleles of the major histocompatibility (MHC)
class II locus further increases this predictive value. Such
prediction is very useful for clinical studies targeted at
T1D prevention given the relatively low incidence of this
disease [7,8]. However, the pathogenic significance of
T1D-related autoantibodies is rather low, if not absent
[9], and the principal effectors of b-cell autoimmune
destruction are CD4+ and CD8+ T lymphocytes [10].
Investigation of specific T-cell responses in T1D patients
is very difficult because of the low frequency in the
peripheral T-cell pool of autoreactive T cells specific
of epitopes derived from (pro)insulin, GAD65 or IA-2.
However, the development of sensitive and specific
techniques, such as enzyme-linked immunosorbant spot
assays (ELISpot) and tetramers of class I/II HLA mol-
ecules complexed with T1D-related epitopes, has already
provided very significant data that further document the
importance of T-cell mediated mechanisms in T1D
pathogenesis [11,12].
Genetic factors in T1D pathogenesis
T1D is the polygenic autoimmune disease that has been
most intensively investigated at the genetic level. Knowl-
edge of genetic loci that determine susceptibility to T1D
is important for identifying pathogenic pathways, for
improved prediction of the disease, and for selection ofCurrent Opinion in Pharmacology 2010, 10:461–472potential pharmacological targets. The balance between
susceptibility and resistance alleles determines individual
predisposition to T1D. The most significant part (50%)
of genetic susceptibility to T1D resides in the HLA class
II region on chromosome 6p21, as recognized by pioneer-
ing studies [13,14]. The major susceptibility in this region
is conferred by the specific HLA class II haplotypes DR4-
DQA1*0301-DQB1*0302 (DQ8 molecule) and DR3-
DQA1*0501-DQB1*0201 (DQ2 molecule). In contrast,
the allele DQB1*0602 (DQ6 molecule) confers dominant
protection against T1D. Theoretically, HLA class I
proteins present antigens that are processed from
endogenous proteins to CD8+ T cells, while HLA class
II proteins present antigens issued from exogenous
proteins to CD4+ T cells. Consequently, it has long been
difficult to explain the relationship between insulin and
T1D genetic susceptibility located in the HLA class II
region. This problem was solved when very elegant
crystallographic studies showed that a dominant insulin
epitope (Ins B9–23) is presented in the binding pocket of
DQ8 and DQ2 proteins [15]. Since then, a comprehen-
sive scan of the whole HLA region, combined with potent
statistical methods, has also linked T1D susceptibility to
HLA class I genes HLA-B and HLA-A [16].
Other genetic linkage and association studies have ident-
ified a second locus for T1D susceptibility that corre-
sponds to a high polymorphic mini-satellite constituted
by a variable number of tandem repeats (VNTR) [17,18].
This VNTR is embedded on chromosome 11p15, and
controls the transcription of the insulin (INS) and insulin-
like growth factor 2 (IGF2) genes downstream. Short
VNTR class I alleles contain 20–63 repeats of 14–15 base
pairs, while intermediate class II and long class III alleles
include 64–139 and 140–210 repeats, respectively. VNTR
class I alleles are associated with TID susceptibility,
whereas class III alleles confer protection.
The CTLA4 gene region on chromosome 2q33 is also
associated with susceptibility to T1D [19]. The signaling
between B7, expressed by professional antigen-present-
ing cells (APCs) such as dendritic cells (DCs) and cyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4),
expressed by T cells, plays a pivotal role in peripheral
T-cell tolerance. CTLA-4 is expressed neither by thy-
mocytes (thymic T cells) nor by resting T cells, but it is
detectable after antigen-mediated T-cell activation, and
downregulates responses of activated T cells. Ctla4
deletion in mice results in an extremely severe lympho-
proliferative and an autoimmune phenotype with lethal
multiorgan tissue destruction [20].
Another mutation in a non-HLA gene conferring signifi-
cant susceptibility to T1D is a variant of the lymphoid
tyrosine phosphatase Lyp gene (PTPN22), a suppressor of
T-cell activation [21]. Lyp normally interacts with a C-
terminal Src kinase (Csk) complex to dephosphorylatewww.sciencedirect.com
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from the T-cell receptor (TCR) pathway. The minor
allele derived from the single-nucleotide polymorphism
(SNP) differs in a single but crucial amino acid residue
(R620W) involved in the interaction of Lyp with Csk.
Interestingly, the same variant R620W also increases risk
to other common autoimmune diseases, such as rheuma-
toid arthritis, Graves’ disease, and systemic lupus erythe-
matosus [22]. However, the variant PTPN22 620W is a
gain-of-function mutant, since it is associated with a
higher catalytic activity of the encoded Lyp, a marked
decrease of T-cell response to antigen stimulation, CD25
expression, and IL-10 secretion from TCR stimulation,
and an increase in peripheral memory CD4+ T cells
[23,24]. The role of this mutation in the pathogenesis
of T1D and other autoimmune diseases remains to be
further elucidated.
Different studies, including a genome-wide association
analysis, have identified association of T1D with noncod-
ing SNPs on the chromosome 10p15 region containing
CD25, which encodes the high-affinity a chain of the
IL2R complex [25]. Further mapping of the association
between the IL2RA locus and T1D supported a role of
IL2Ra in the pathogenesis of the disease, most possibly
through modulation of regulatory T-cell (Treg) activity
[26].
An association has also been found between T1D and a
polymorphism of the IGF2 receptor gene (IGF2R), which
seems to be subject to parental imprinting since only
maternal alleles at this polymorphism are associated with
the disease [27]. Human T1D differs from other common
autoimmune disorders, which preferentially affect
females (e.g. autoimmune diabetes in the NOD mouse).
Evidence was also recently provided for an association
between T1D and polymorphisms in CYP27B1, which
encodes 1a-hydroxylase, the enzyme that transforms
25(OH) vitamin D into bioactive 1,25(OH)2 vitamin
D3 [28].
Environmental factors
Many observations strongly support an important influ-
ence of environmental factors in the pathogenesis of
T1D: the lack of complete concordance in monozygotic
twins (approximately 30% of them developT1D), the fact
that less than 10% of genetically susceptible individuals
progress to overt disease, the increase in T1D annual
incidence observed in recent years, as well as the higher
incidence of new cases between March and October.
Geographic localization also determines important vari-
ation in T1D incidence when one compares high-rated
Northern European countries such as Finland (40–45 new
cases/100 000 inhabitants per year) and low-rated
countries such as Venezuela and China (0.1/100 000
inhabitants per year) [29]. Migrant populations moving
from low-incidence countries tend to acquire the samewww.sciencedirect.comrisk as the inhabitants of the welcoming countries. For
example, T1D annual incidence among Pakistani chil-
dren living in United Kingdom is identical to that
observed among English children (e.g. 11.7/100 000
inhabitants versus 1/100 000 inhabitants in Pakistan)
[30]. However, migrant studies also provide evidence
for the importance of genetic background, since the risk
of T1D remains increased for people migrating from
high-incidence areas to low-risk countries [31]. In
Europe, a 10-fold North–South gradient is observed in
T1D incidence (with the noticeable exception of Sardinia
for unknown reasons). Owing to the relative homogeneity
of European populations, such a gradient cannot result
from genetic differences only. Although childhood T1D
was rare and lethal at the beginning of the 20th century, a
recent European Community Concerted Action Program
(EURODIAB) has shown that new T1D cases in Euro-
pean children under 5 years is predicted to double be-
tween 2005 and 2020, and prevalence of T1D cases under
15 years will rise by 70% [32]. As discussed by the authors,
these rapid changes over relatively short periods of time
cannot be explained by changes in prevalence of suscepti-
bility genes. Among environmental influences, several
studies have pointed to modern lifestyle habits, increased
weight and height, increased caesarean deliveries and,
most perhaps importantly, the ‘hygiene hypothesis’. This
hypothesis proposes that the decrease of childhood infec-
tions and other environmental stimuli impair the healthy
development and diversification of the neonatal immune
repertoire, inducing higher incidence of allergic and
autoimmune diseases later in life [33,34]. In the
NOD mouse, a classic animal model of T1D, the
susceptibility to autoimmune diabetes is also greatly
affected by environmental effects, and the incidence of
the disease is much higher when NODmice are bred in a
germ-free environment [35].
A number of viral infections have also been associated
with the subsequent development of T1D including
enteroviruses, congenital rubella, mumps, cytomegalo-
virus, Epstein–Barr virus, and varicella zoster virus
[36,37]. Epidemiological studies have provided the stron-
gest evidence that coxsackievirus (CVB) and other enter-
ovirus infections are frequent events in subjects who
ultimately develop T1D [38]. CVB4 is the most common
serotype detected in prediabetic and diabetic individuals.
The CVB4 strain E2 has been isolated from the pancreas
of an acutely deceased diabetic child, passed through
murine islet b cells, and then found to induce a dia-
betes-like disease after inoculation in mice [39]. Early
epidemiologic studies have suggested that CVB may be
involved in T1D pathogenesis. Using serological
analyses, initial first studies showed that newly diagnosed
T1D patients were more frequently positive for CVB4
than control subjects [40,41]. Subsequently, a series of
epidemiological studies have confirmed high frequencies
of IgM anti-CVB in children recently diagnosed withCurrent Opinion in Pharmacology 2010, 10:461–472
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genome, Clements et al. showed that 64% of children at
onset of T1D were positive for enteroviruses as opposed
to 4% of controls [42]. In another study, CVB genome was
detected in five out of 12 (42%) newly diagnosed T1D
patients and in one of 12 (8%) patients during the course
of the disease. By contrast, none of 12 T2D patients and
none of 15 healthy adults had enterovirus sequences in
their blood [43]. The CVB4 strain E2 is able to induce a
persistent infection of human islet b cells [44], whereas a
new isolated CVB4 variant, VD2921, causes a persistent
infection of islet b cells with a consequent disturbance of
proinsulin synthesis and insulin secretion [45]. CVB4 E2
and VD2921 genomes were recently detected by RT-
PCR in the peripheral blood mononuclear cells (PBMCs)
of a majority of T1D children at the onset of their
diabetes. The presence of enterovirus RNA in the blood
cells of most new T1D children supports the hypothesis
that a viral infection is involved in T1D pathogenesis.
Interestingly, six out of seven controls positive for CVB4
had been infected by a phylogenetic branch of CVB4
different from the one detected in diabetic patients,
suggesting the existence of CVB4-related substrains with
different diabetogenic effects [46].
Despite a significant homology between the amino acid
sequence 28–50 of P2-C, a nonstructural viral protein of
the CVB4 replicative complex, and amino acids 250–273
of the b-cell autoantigen GAD65, molecular mimicry is
not involved in CVB-induced diabetes, as mice with
susceptible MHC alleles do not show CVB-induced
acceleration of diabetes [47]. Moreover, none of anti-
GAD65 antibodies produced by lymphocytes isolated
from a newly diagnosed T1D patient crossreacted with
the protein P2-C itself [48]. Nevertheless, it was shown
that a viral epitope mimicking a b-cell antigen is able to
accelerate, but not to prime a diabetogenic autoimmune
process [49]. A very recent study has also identified a
molecular mimicry between human T-cell epitopes in
rotavirus and pancreatic islet autoantigens (GAD65 and
IA-2) [50].
An alternative potential mechanism is a CVB-mediated
‘bystander’ activation of autoreactive T cells against islet
antigens; this mechanism was proposed to explain the
rapid onset of diabetes in mice carrying a TCR specific for
a sequestered islet autoantigen. In that model, CVB
induces diabetes by a direct local infection, leading to
inflammation, secondary tissue damage, and then release
of sequestered islet antigens that are able to stimulate
resting autoreactive T cells [47]. According to those
observations, autoreactive T lymphocytes would gain
access to the target islets without being involved in the
initial viral insult or in reactivity to the viral antigens [51].
The same group also provided strong evidence that the
early innate immune response to CVB4 is responsible for
b-cell damage and the development of diabetes. Indeed,Current Opinion in Pharmacology 2010, 10:461–472b cells became highly susceptible to CVB4 infection and
subsequent NK cell response after inhibition of inter-
feron (IFN) signaling by transgenic overexpression in
islet b cells of suppressor of cytokine signaling 1
(SOCS-1) under the influence of the insulin promoter.
The islet b cells were secondarily damaged by apoptosis
occurring during the innate immune response, rather than
by the adaptive B-cell and T-cell responses. Thus, target
b cell defense critically influences susceptibility to T1D
after CVB4 infection [52].
Although the relationships between CVB infection and
subsequent T1D development are still debated by some
authors, recent studies using PCR techniques with very
specific oligonucleotide probes — thus avoiding serolo-
gical pitfalls and crossreactions — have found substantial
evidence for an association between a previous CVB
infection and T1D. High levels of IFN-a, an indirect
indicator of viral infection, were measured in 70% of 56
new type 1 diabetics, together with positive detection of
CVB RNA in 50% of the IFN-a positive patients [53].
Somewhat ironically, the association between T1D and
viral infections has been recently reinforced by genetic
studies that have shown a linkage between T1D suscepti-
bility and host genetic determinants of the antiviral
responses such as the antiviral oligoadenylate synthetase
(OAS1) and the interferon-induced helicase (IFIH1 or
MDA5), which intervenes in innate immunity by recog-
nition of RNA genomes of picornaviruses (such as coxsa-
kieviruses) [54–56]. Therefore, the question of a higher
incidence of enterovirus infection during childhood in
countries with a high risk of T1D deserves to be further
investigated, particularly if one seriously considers the
possibility of anti-CVB vaccination as a potential method
for T1D prevention in these areas.
The central role of the thymus in self-
tolerance of neuroendocrine proteins and the
nature of ‘neuroendocrine self’
A major question when addressing the pathogenesis of
organ-specific autoimmunity such as T1D is the origin of
the self-reactive T cells that are directed against target
antigens of endocrine cells. Among all lymphoid struc-
tures, the thymus is an organ that emerged some 500
million years ago, concomitantly or very shortly after
recombinase-dependent adaptive immunity, with a
specific function of orchestrating central immunological
self-tolerance. The thymus is not an endocrine gland, but
it crucially stands at the intersection between the
immune and neuroendocrine systems. In this organ that
is responsible for thymopoiesis, that is, generation of
naı¨ve and competent T lymphocytes, the neuroendocrine
system regulates the process of T-cell differentiation
from very early stages, while in parallel naı¨ve T lympho-
cytes are educated to recognize and tolerate neuroendo-
crine gene/protein families [57,58,59]. Therefore, the
thymus is a unique organ where a constant conflict occurswww.sciencedirect.com
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proteins and a more recently evolved system equipped
with recombination machinery for promoting stochastic
generation of T-cell response diversity. Contrary to pop-
ular opinion, the thymus continues to function through-
out life and plays a fundamental role in the recovery of a
competent T-cell repertoire after intensive chemother-
apy or during highly active antiretroviral chemotherapy in
human immunodeficiency virus infection [60,61]. The
integrity of the somatotrope growth hormone/IGF-1 axis
is known to be important for the maintenance of thymus
function in adult life [62].
The thymus constitutes the central arm of immunological
self-tolerance by two essential mechanisms that are inti-
mately associated with, and paradoxically mediated by,
the same thymic self-antigens: first, clonal deletion of
self-reactive T cells issued from the random recombina-
tion of TCR genes (negative selection) and second,
generation of self-antigen-specific natural regulatory T
cells (nTregs) that are able to inactivate in periphery self-
reactive T cells having escaped intrathymic negative
selection [63,64].
For a long time, peripheral tissue-restricted antigens
targeted by autoimmune processes were thought to be
sequestered from T cells during their intrathymic differ-
entiation. We and several other groups have demon-
strated that thymic epithelial cells (TECs) from
different species constitute a site for the promiscuous
transcription of a great number of genes encoding tissue-
restricted antigens or belonging to neuroendocrine
families, such as the neurohypophysial family, tachyki-
nins, neurotensins, somatostatins, atrial natriuretic pep-
tides, and the insulin family. This demonstration has
radically changed our common understanding of the
pathogenesis of organ-specific autoimmune endocrine
diseases such as T1D. From the investigation of intrathy-
mic expression of neuroendocrine-related self-peptide
precursor genes, a series of properties can be derived
that define the nature of the ‘neuroendocrine self’. First,
thymic neuroendocrine self-antigens usually correspond
to peptide sequences that have been highly conserved
throughout the evolution of their related family. Second,
a hierarchy characterizes their expression pattern in the
thymus. In the neurohypophysial family, oxytocin (OT) is
the dominant peptide synthesized by TECs from differ-
ent species. The binding of OT to its cognate receptor
expressed by pre-T cells induces a very rapid phosphoryl-
ation of focal adhesion related kinases. This event could
play a major role in promoting establishment of synapses
between immature T lymphocytes and thymic APCs,
TECs, macrophages, and DCs. With regard to tachyki-
nins, neurokinin A (NKA) — but not substance P — is
the peptide generated from the processing by TEC of the
preprotachykinin A (PPT-A) gene product. All the genes
of the insulin family are expressed in the thymus accord-www.sciencedirect.coming to a precise hierarchy and topography during fetal life:
IGF2 (cortical and medullary TECs) > IGF1 (thymic
macrophages) INS (a few subsets of medullary TECs).
This hierarchical pattern is meaningful because the
strength of self-tolerance to a protein is proportional to
its intrathymic concentration [65]. Third, neuroendocrine
precursors are not processed according to the classic
model of neurosecretion, but they undergo an antigenic
processing for presentation by — or in association
with —MHCproteins [66]. Fourth, most of neuroendo-
crine self-antigens are transcribed in the thymic epi-
thelium under the control of the autoimmune regulator
gene AIRE (see below). Fifth, intrathymic OT transcrip-
tion precedes OT and vasopressin (VP) expression in
hypothalamic magnocellular neurons. Finally, epigenetic
regulation of intrathymic gene expression is strongly
suggested by the loss of IGF2 parental imprinting and
overexpression in human medullary TECs [67,68].
This hierarchy in the organization of the thymic reper-
toire of neuroendocrine self-antigens is also significant
from an evolutionary point of view. Since a series of
essential and physiological functions had been estab-
lished before the appearance of adaptive immunity in
cartilaginous fishes, they had to be protected from the risk
of autotoxicity inherent to this type of immunity. For
example, OT is a ‘bonding’ peptide that has been impli-
cated at different steps of the reproductive process, and
thus for species preservation possibly had to be protected
to a greater degree than VP, which controls water metab-
olism and vascular tone. Along the same line of reasoning,
IGF-2 as a major factor in fetal development possibly had
to be more protected than insulin, which is ‘only’ respon-
sible for glucose homeostasis. Nevertheless, because of
their close homology, thymic neuroendocrine self-anti-
gens may promote crosstolerance to other members of
their respective families. This was recently demonstrated
by the weaker tolerance to insulin of Igf2/ mice when
compared to wild-type mice [69]. Further insight into
the discrimination between the relative influence of
central and peripheral arms of immunological self-toler-
ance will be gained through the generation of mice with
TEC-specific Igf2 deletion, currently under development
in our laboratory.
The central role of a thymus dysfunction in
T1D pathogenesis (Figure 1)
As hypothesized by Burnet in 1973, the essential patho-
genesis of autoimmune diseases may first depend on the
appearance of ‘forbidden’ self-reactive clones in the
peripheral T-cell repertoire [70]. In 1992, a defect in
the process of intrathymic T-cell education to recognize
and to tolerate OT was hypothesized to play a pivotal role
in the development of hypothalamus-specific autoimmu-
nity leading to ‘idiopathic’ central diabetes insipidus [71].
The progressive increase in the degree of immune diver-
sity and complexity may explain why failures in self-Current Opinion in Pharmacology 2010, 10:461–472
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most such failures occurring in the human species. Since
the thymus is the primary site for induction of self-
tolerance, thorough investigation of the mechanisms
responsible for a breakdown of thymus-dependent toler-
ance should provide the scientific community with
important keys to understand themechanisms underlying
the development of autoimmune responses. This was the
principal objective of the European FP6 Integrated Pro-
ject Euro-Thymaide. A number of abnormalities of thy-
mic morphology and cytoarchitecture have been
described for several autoimmune disorders. Central tol-
erance and apoptosis of self-reactive T cells are defective
in the thymus of NOD mouse [72,73]. Transcription of
insulin-related genes (Ins, Igf1, and Igf2) has been ana-
lyzed in the thymus of diabetes-resistant (BBDR) and
diabetes-prone (BBDP) rats, another model of T1D. Ins
and Igf1 transcripts were detected in all thymi fromBBDP
and BBDR rats. Igf2 transcripts were also present in the
thymus from all BBDR rats, but were not detected in the
thymus from more than 80% of BBDP rats, in close
concordance with the incidence (86%) of autoimmune
diabetes in those rats. This defect in Igf2 transcription in
BBDP thymus could contribute to both their lymphope-
nia (including CD8+ T cells and suppressor/regulatory
RT6+ T cells) and to the absence of central self-tolerance
to insulin-secreting islet b cells [74,75]. Other authors
have shown that susceptibility to autoimmune diabetes is
correlated with the level of Ins2 transcription in the
mouse thymus [76]. Breeding of Ins2/ mice onto the
NOD background markedly accelerated insulitis and
onset of diabetes [77]. In contrast, insulitis and diabetes
were considerably reduced in Ins1/ congenic NOD
mice [78]. These observations are explained by the
dominance of Ins2 encoding proinsulin in the murine
thymus, while Ins1 encodes proinsulin in islet b cells.
In the human species, INS transcripts were measured at
lower levels in the fetal thymus with short class I VNTR
(variable number of tandem repeats) alleles, a genetic
trait of T1D susceptibility as discussed above [79,80].
The fundamental role of thymic insulin in mediating
central self-tolerance of islet b cells was definitively
demonstrated by the rapid onset of autoimmune diabetes
following thymus-specific deletion of Ins1 and Ins2
through an elegant transgenic construction in mice [81].
The identification of AIRE led to further demonstration
that a thymus dysfunction plays a crucial role in the
pathogenesis of organ-specific autoimmune diseases
[82,83]. Loss-of-function AIRE single mutations are
responsible for a very rare autosomal recessive disease
named autoimmune polyendocrinopathy, candidiasis and
ectodermal dystrophy (APECED), or autoimmune poly-
endocrine syndrome type 1 (APS-1). This syndrome
develops in early childhood and is characterized by multi-
organ autoimmunity and insufficiency of several endo-
crine glands such as parathyroids, adrenal cortex, andCurrent Opinion in Pharmacology 2010, 10:461–472gonads. AIRE codes for a 54-kDa protein sharing struc-
tural characteristics with transcription factors. Its expres-
sion is maximal in the thymus, mainly in medullary
TECs, but is absent in TECs of NOD mice [84].
Depending on their genetic background, Aire/ mice
exhibit several signs of peripheral autoimmunity, which
are associated with a significant decrease in thymic tran-
scription of neuroendocrine genes (includingOt,Npy, Igf2,
and Ins2), as well as other tissue-specific genes
[85,86,87]. Of note, Aire deficiency on NOD back-
ground induces both wasting and resistance to diabetes,
while autoimmunity severely affects pancreatic exocrine
acini [88].
In collaboration with Didier Hober (Laboratory of Virol-
ogy EA3610, CHRU Lille, France), we have shown that
CVB4 is capable to directly infect the epithelial and
lymphoid compartments of the human and murine thy-
mus, and to induce a severe thymus dysfunction with
massive pre-T-cell depletion and marked upregulation of
MHC class I expression by TECs and by CD4+ CD8+
immature thymic T cells [89,90]. Interestingly, outbred
mice can be infected with CVB4 following an oral inocu-
lation, which results in systemic spreading of viral RNA
and a prolonged detection of CVB4 RNA in thymus,
spleen, and blood up to 70 days postinoculation [91].
These findings suggest that thymic CVB4-mediated
severe infection could enhance CVB4 virulence through
induction of immunological tolerance to CVB4, and con-
sequently may play a role in the breakdown of central
self-tolerance to islet b cells.
Self-vaccination as an alternative for T1D
prevention and cure (Figure 2)
Given the impossibility to modify the genetic consti-
tution of susceptible individuals and to act efficiently
upon most of the environmental influences — except
perhaps through a future anti-enterovirus/CVB4 vaccina-
tion in high-risk countries — contemporary clinical
results still favor an immunomodulatory approach aiming
to control the autoimmune response oriented against b
cells, but without compromising general immunity. Ide-
ally, this autoimmune regulation should be combined
with strategies of regeneration of damaged islet b cells
and the inhibition of the apoptotic process promoted in b
cells by the autoimmune process. Nevertheless, even
after transplantation of b cells from allogenic or xenogenic
donors, or b cells issued from adequate differentiation of
embryonic stem cells or induced pluripotent stem cells,
the control of autoimmune memory selective of islet b
cells is an absolute prerequisite both for T1D prevention
and for cure. Until now, significant clinical success has
been reached only with Fc receptor (FcR)-nonbinding
CD3-specific humanized monoclonal antibodies that
were shown to preserve endogenous insulin-secreting
islet b-cell mass in recently diagnosed T1D patientswww.sciencedirect.com
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Figure 1
Thymus physiopathology and T1D development. Throughout life, the thymus selects Teff self-tolerant and competent against nonself-antigens, and
generates self-specific nTregs. Thymic epithelium transcribes genes encoding T1D-related antigens, as well as other neuroendocrine-related and
tissue-restricted antigens, under AIRE control for most of them. Absence or decrease in the presentation of thymic T1D-related antigens (as observed
in different animal models of autoimmune diabetes) conducts to the enrichment of the peripheral T-cell pool with ‘forbidden’ self-reactive T cells
bearing TCR directed against T1D-related epitopes, while thymic generation of specific nTregs is severely impaired. Combination of these two events
is responsible for the breakdown of central self-tolerance to islet b cells. Both genetic and environmental factors are involved in the establishment of a
molecular bridge between anti-b cell autoreactive Teff and islet b-cell autoantigens. Once this bridge is formed, the autoimmune pathogenic response
is triggered and leads to a progressive reduction of the b-cell mass.[92,93]. This strategy of immunomodulation in T1D
has been extensively discussed elsewhere [94].
Because of its antigen-specificity, the most attractive
immunomodulating approach is the design of peptide-
based therapeutic vaccines [95–97]. A recent randomized,
placebo-controlled clinical trial has shown that two sub-
cutaneous injections of GAD65 (20 mg) in a standard
vaccine formulation with alum (GAD-alum) contribute
to the preservation of residual insulin secretion in recent-
onset T1D, but did not change the insulin requirement
[98,99]. According to the novel knowledge gained in T1D
pathogenesis and the central role of a thymus dysfunction
in its development, the control of the autoimmune pro-
cess could be obtained by (re)programing b-cell through
the potent tolerogenic properties of the thymus, in
particular the repertoire of thymic T1D-related self-anti-
gens. According to this perspective, the profile of cytokine
secretion was analyzed after presentation of Ins B9–23, a
major T1D autoantigen [5,6], and the homologous
sequence IGF-2 B11–25 derived from IGF-2, the domi-
nant thymic self-antigen of the insulin family. This studywww.sciencedirect.comwas performed in PBMC cultures derived from DQ8-
positive T1 adolescents. First, InsB9-23 and IGF-2 B11-
25 were shown to have the same affinity and to compete
for binding to DQ8 and DQ2 (Wu¨cherpfennig and Gee-
nen, unpublished data). Second, using ELISpot method-
ology, DQ8 presentation of IGF-2 B11 25 was found to
induce a regulatory profile ("IL-10, "IL-10/IFN-g, and
"IL-4), statistically different from the profile induced by
Ins B9–23. This regulatory profile could derive from a
different cytokine profile secreted by Ins B9–23-reactive
CD4+ T cells in response to IGF-2 B11–25, or from the
recruitment and activation of IGF-2 specific Tregs. So,
contrary to insulin, the ‘altered self-IGF-2’, IGF-2 and
derived epitopes might be a much more appropriate
choice for a novel type of a negative self-vaccination that
associates competition for MHC presentation and regu-
latory responses downstream, as well as potential bystan-
der suppression of autoimmune responses to other T1D-
related autoantigens. This hypothesis is currently being
investigated by vaccination of NOD mice with recombi-
nant human IGF-2 alone or in combination with adju-
vants. A very recent study has shown that the combinationCurrent Opinion in Pharmacology 2010, 10:461–472
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Figure 2
Principles of negative/tolerogenic self-vaccination. These principles are based on homology and crosstolerance between IGF-2 and insulin.
Intrathymic presentation of IGF-2 as the self-antigen of the insulin family leads to clonal deletion of IGF-2 reactive T cells and generation of IGF-2
specific nTregs. The diabetogenic autoimmune response results from recognition of insulin (as ‘altered IGF-2’) and activation of anti-insulin Teff having
escaped thymic censorship. It could also be facilitated by the unproved absence of insulin-specific nTregs. IGF-2 antigenic epitopes compete with
homologous insulin sequences for binding to MHC, and their recognition by anti-insulin TCRs might promote a regulatory response ("IL-10, "IL-4)
instead of an inflammatory Th1 profile.of antigen-based therapy with FcR-nonbinding CD3-
specific monoclonal antibody strongly increased the
activity of insulin-specific Foxp3+ CD4+ CD25+ Tregs.
These cells could transfer dominant tolerance to immu-
nocompetent recent-onset diabetic mice recipients, and
they were shown to secrete IL-10, TGF-b, and IL-4, thus
strongly suggesting induction of antigen-specific Tregs
[100]. Finally, with regard to generation of islet b cells
from human induced pluripotent stem cells, IGF-2 was
used with nicotinamide for the final differentiation of
pancreatic exocrine/endocrine cells into insulin-produ-
cing cells [101]. It is notable that these results suggest
that the same protein, IGF-2, can be employed both to
regenerate the functional b-cell mass and to reprogram of
immunological tolerance to islet b cells.
Conclusion
The thymus plays a central role in the establishment of
central immunological self-tolerance toward Langerhans’
insulin-secreting islet b cells, and there is now evidence
that the development of T1D results from a breakdown of
thymus-dependent tolerance of insulin-family derived
epitopes. This knowledge should translate in the very
near future to the design of novel tolerogenic/regulatory
approaches aimed at restoring the immunological toler-
ance specific of islet b cells, which represents an appeal-
ing strategy for both the prevention and the cure of T1D,Current Opinion in Pharmacology 2010, 10:461–472one of the heaviest prices paid by the human species for
having evolved the advantage of the extreme diversity
and efficiency of adaptive immune responses against new
biological threats.
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